Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Engage Grants Program

University of British Columbia

$25,000.00

Distribution kinetics of cell permeable protein in a biological system using radioisotope imaging

EF 2013-14

Résumé
Cell permeable proteins are the engineered recombinant proteins designed to permeate into the cytoplasm ofcells. Although cell permeable protein has a great therapeutic potential, its commercialization has beenhindered due to a lack of specificity in targeting selected cells and cell types. Without a specific targetingmechanism, the cell permeable proteins enter to whatever cells the proteins first come into contact with. Thiscan potentially create an unwanted side effect and lower the overall biological efficacy of the treatment.iProgen's goal is to overcome the current challenge by engineering an antibody-mediated targeting modalityinto current cell permeable protein therapeutics, so that proteins can be targeted to specific cells in a biologicalsystem before they permeate into those cells.For this project, iProgen will produce cell permeable red fluorescent proteins with and without antibodytargeting modality. We will incorporate antibody targeting modality against pancreas alpha cells. Dr. Hafeli'sgroup will use the Single Photon Emission Computed Tomography (SPECT) radioisotope 67Ga to label thecell permeable protein (control; Pcont) and the cell permeable protein with antibody targeting modality(experimental group; PAb). The radiolabeled protein samples will be injected into two groups of mice. SPECTimaging will then be used to examine the protein biodistribution pattern and kinetics in these mice, andquantitate and compare the effect of the antibody-mediated targeting modality on the transduction of cellpermeable proteins to pancreatic alpha cells.
Programme
Engage Grants Program
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
460805-2013
Name nom
Hafeli, Urs
Department département
Pharmaceutical Sciences, Faculty of
Organization id
2
Institution établissement
University of British Columbia
Province en
British Columbia
Province fr
Colombie-Britannique
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2013
Competition year année de concours
2013
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1554
Committee name en
Pacific Internal Decision Committee
Committee name fr
Comité de décision interne pour le Pacifique
Area of application code
1211
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Medical and health sciences
Area of application fr
Sciences médicales et de la santé
Research subject code
9000
Research subject group en
Medical sciences
Research subject group fr
Sciences médicales
Research subject en
Medical sciences
Research subject fr
Sciences médicales
Partie
1
Nb partie
1
Application title
Distribution kinetics of cell permeable protein in a biological system using radioisotope imaging
Keyword
NSERC
Application summary
Cell permeable proteins are the engineered recombinant proteins designed to permeate into the cytoplasm ofcells. Although cell permeable protein has a great therapeutic potential, its commercialization has beenhindered due to a lack of specificity in targeting selected cells and cell types. Without a specific targetingmechanism, the cell permeable proteins enter to whatever cells the proteins first come into contact with. Thiscan potentially create an unwanted side effect and lower the overall biological efficacy of the treatment.iProgen's goal is to overcome the current challenge by engineering an antibody-mediated targeting modalityinto current cell permeable protein therapeutics, so that proteins can be targeted to specific cells in a biologicalsystem before they permeate into those cells.For this project, iProgen will produce cell permeable red fluorescent proteins with and without antibodytargeting modality. We will incorporate antibody targeting modality against pancreas alpha cells. Dr. Hafeli'sgroup will use the Single Photon Emission Computed Tomography (SPECT) radioisotope 67Ga to label thecell permeable protein (control; Pcont) and the cell permeable protein with antibody targeting modality(experimental group; PAb). The radiolabeled protein samples will be injected into two groups of mice. SPECTimaging will then be used to examine the protein biodistribution pattern and kinetics in these mice, andquantitate and compare the effect of the antibody-mediated targeting modality on the transduction of cellpermeable proteins to pancreatic alpha cells.